Novimmune, LegoChem to collaborate on antibody drug conjugate research
Swiss biotech company Novimmune and South Korea based LegoChem Biosciences (LCB) have entered into a research collaboration to evaluate an antibody drug conjugate candidate.
LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology.
In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in January 2017, signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.
Novimmune Chairman and CEO Eduard Holdener said: “Our antibody expertise married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients.”
ADCs are molecules composed of a tumor specific monoclonal antibody linked to a cytotoxic agent. Unlike chemotherapy, they are intended to target only cancer cells and spare healthy cells.
Novimmune brings expertise in the field of targeted therapies with their anti-CD47/anti-CD19 and anti-CD47/anti-mesothelin bispecific antibodies that selectively bind to hematological and solid tumors, respectively.
Source: Company Press Release